Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 7, Issue 6, 2007, Pages 559-576

  Lam, Raymond W ^a   Annemans, Lieven ^b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b GHENT UNIVERSITY   (Belgium)

^c FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Anxiety disorders; Cost effectiveness; Escitalopram; Health outcomes; Major depressive disorder; Obsessive compulsive disorder; Panic disorder; Pharmacoeconomics

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GENERIC DRUG; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANXIETY DISORDER; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISABILITY; DISEASE SEVERITY; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENERALIZED ANXIETY DISORDER; HEALTH ECONOMICS; HUMAN; MAJOR DEPRESSION; MIXED ANXIETY AND DEPRESSION; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PRODUCTIVITY; RECOMMENDED DRUG DOSE; REMISSION; RESOURCE MANAGEMENT; SOCIAL ASPECT; SOCIAL PHOBIA;

EID: 37549007581     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.7.6.559     Document Type: Article

References (105)

1. Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289(23), 3095-3105 (2003).
2. Kessler RC, McGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry 51(1), 8-19 (1994).
3. Nutt DJ. Care of depressed patients with anxiety symptoms. J. Clin. Psychiatry 60(Suppl. 17), 23-27; discussion 46-48 (1999).
4. Lenze EJ, Mulsant BH, Shear MK et al. Comorbid anxiety disorders in depressed elderly patients. Am. J. Psychiatry 157(5), 722-728(2000).
5. Rouillon F. Anxiety with depression: a treatment need. Eur. Neuropsychopharmacol. 9(Suppl. 3), S87-S92 (1999).
6. Lydiard RB. Social'anxiety disorder: comorbidity and its implications. J. Clin. Psychiatry 62(Suppl. 1), 17-23; discussion 24(2001).
7. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J. Clin. Psychiatry 60(Suppl. 22), 29-34 (1999).
8. Mittal D, Fortney JC, Pyne JM, Edlund MJ, Wetherell JL. Impact of comorbid anxiety disorders on health-related quality of life among patients with major depressive disorder. Pychiatr. Serv. 57(12), 1731-1737 (2006).
9. Thase ME. Treatment of severe depression. J. Clin. Psychiatry 61 (Suppl. 1), 17-25 (2000).
10. Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs 15(10), 765-776 (2001).
11. Olesen J, Leonardi M. The burden of brain diseases in Europe. Eur. j. Neurol. 10(5), 471-477 (2003).
12. Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. J. Ment. Health Policy Econ. 9(2), 87-98 (2006).
13. Greenberg PE, Kessler RC, Birnbaum HG et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry 64(12), 1465-1475 (2003).
14. Sobocki P, Ekman M, Agren H et al. Resource-use and cost of patients treated for depression in primary care. Presented at: The 11th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Philadelphia, PA, USA, 20-24 May 2006 (Abstract PMH17).
15. Berto P, D'Ilario D, Ruffo P, Di Virgilio R, Rizzo F. Depression: cost-of-illness studies in the international literature, a review. J. Ment. Health Policy Econ. 3(1), 3-10 (2000).
16. Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int. Clin. Psychopharmacol. 19(5), 305-310 (2004).
17. Rush AJ, Kraemer HC, Sackeim HA et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 31(9), 1841-1853 (2006).
18. Sobocki P, Ekman M, Agren H, Runeson B, Jonsson B. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int. J. Clin. Pract. 60(7), 791-798 (2006).
19. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry 50(5), 345-350 (2001).
20. Baldwin DS, Reines EH, Guiton C, Weiller E. Escitalopram therapy for major depression and anxiety disorders. Ann. Pharmacother. 41(10), 1583-1592 (2007).
21. Mork A, Kreilgaard M, Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45(2), 167-173 (2003).
22. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 174(2), 163-176 (2004).
23. Cipralex® Product Monograph. H. Lundbeck A/S. Copenhagen, Denmark. (2007).
24. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J. Clin. Psychiatry 63(4), 331-336 (2002).
25. Colonna L, Reines EH, Andersen HF. Escitalopram is well-tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients. Int. J. Psychiatry Clin. Pract. 6, 243-244 (2002) (Abstract P205).
26. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Pychopharmacol. 18(4), 211-217 (2003).
27. Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Pychopharmacol. 17(3), 95-102 (2002).
28. Demyttenaere K, Hemels ME,Hudry J, Annemans L. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin. Ther. 27(1), 111-124 (2005).
29. Francois C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between other SSRIs and SNRI for the treatment of depression and estimation of budgetary impact. J. Drug Assess. 5, 221-237 (2002).
30. Francois C, Toumi M, Aakhus AM, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur. J. Health Econ. 4(l), 12-19 (2003).
31. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382-389 (1979).
32. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23, 56-62 (1960).
33. Lam RW, Michalak EE, Swinson RP. Assessment Scales in Depression, Mania and Anxiety. Taylor & Francis, London, UK 84-85(2005)
34. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J. Clin. Psychiatry 65(1), 44-49 (2004).
35. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int. Clin. Psychopharmacol. 20(3), 131-137 (2005).
36. Boulenger JP, Huusom. AK, Florea. I, Baekdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr. Med. Res. Opin. 22(7),1331-1341 (2006).
37. Auquier P, Robitail S, Llorca P-M, Rive B. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int. J. Psych. Clin. Pract. 7(4), 259-268 (2003).
38. Lancon C, Verpillat P, Annemans L, Despiegel N, Francois C. Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram. Int. J. Psych. Clin. Pract. 11(1), 44-52 (2007).
39. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J. Psychiatry Neurosci. 31(2), 122-131 (2006).
40. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr. Med. Res. Opin. 23(7), 1605-1614 (2007).
41. Khan A, Bose A, Alexopoulos GS et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin. Drug Investig. 27(7), 481-492 (2007).
42. Nierenberg AA, Greist JH, Mallinckrodt CH et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr. Med. Res. Opin. 23(2), 401-416 (2007).
43. Azorin JM, Llorca PM, Despiegel N, Verpillat P. Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder. Encephale 30(2), 158-166 (2004).
44. Llorca PM, Azorin JM, Despiegel N, Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int. J. Clin. Pratt. 59(3), 268-275 (2005).
45. Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry 39(5), 180-184 (2006).
46. Dhillon S, Scott LJ, Plosker GL. Escitalopram: a review of its use in the management of anxiety disorders. CNS Drugs 20(9), 763-790 (2006).
47. Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress. Anxiety 19(4), 234-240 (2004).
48. Baldwin DS, Huusom AK, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br. J. Psychiatry 189, 264-272 (2006).
49. Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J. Affect. Disord. 87(2-3), 161-167 (2005).
50. Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann. Clin. Psychiatry 17(2), 65-69 (2005).
51. AlIgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int. J. Neuropsychopharmacol. 9(5), 495-505(2006).
52. Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J. Clin. Psychiatry 66(10), 1270-1278(2005).
53. Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br. J. Pychiatry 186(3), 222-226 (2005).
54. Pallanti S, Quercioli L. Resistant social anxiety disorder response to escitalopram. Clin. Pract. Epidemol Ment. Health 2, 35 (2006).
55. Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress. Anxiety 19(4), 241-248 (2004).
56. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 64(11), 1322-1327(2003).
57. Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Escitalopram in obsessive - compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr. Med. Res. Opin. 23(4), 701-711 (2007).
58. Fineberg NA, Tonnoir B, Lemming O, Stein DJ. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur. Neuropsychopharmacol. 17(6-7), 430-439 (2007).
59. Jorgensen TR, Stein DJ, Despiegel N et al. Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. Ann. Pharmacother. 40(10), 1752-1758(2006).
60. Erder MH, Sharma D, Saikali K. A comparison of total direct costs of escitalopram vs. paroxetine in generalized anxiety disorder (GAD). Presented at: the 6th European Conference on Health Economics. Budapest, Hungary, 6-9 July 2006 (P62).
61. Erder MH, Sharma D, Saikali K. A comparison of total direct costs of escitalopram vs. paroxetine in generalized anxiety disorder (GAD). Presented at: the 26th AnnualMeeting of the Anxiety Disorders Association ofAmerica. Miami, FL, USA, 23-26 March (2006) (P379).
62. Servant D, Montgomery SA, Francois C, Despiegel N. Cost - effectiveness of escitalopram versus placebo in relapse prevention in patients with social anxiety disorder. Presented at: The 8th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Arlington, VA, USA 18-21 May 2003 (Abstract PMH2).
63. Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr. Med. Res Opin. 21(10), 1659-1668 (2005).
64. Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J. Clin. Psychiatry 59(Suppl. 8), 47-54 (1998).
65. Rudolph RL. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors. Acta Pychiatr. Scand. 415(Suppl.), 24-30 (2002).
66. Bren L. The importance of patient-reported outcomes. It's all about the patients. FDA Consum. 40(6),26-32 (2006).
67. Ringash J, O'Sullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. Cancer 110(l), 196-202 (2007).
68. Svanborg P, Asberg M. A new self-rating scale for depression and anxiety states based on the Comprehensive Psychopathological Rating Scale. Acta Psychiatr. Scand. 89(1), 21-28 (1994).
69. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol. Bull. 29(2), 321-326 (1993).
70. Bech P, Tanghoj P, Cialdella P, Andersen HF, Pedersen AG. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int. J. Neuropsychopharmacol. 7(3), 283-290 (2004).
71. Allgulander C, Jorgensen T, Wade A et al. Health-related quality of fife (HRQ0L) among patients with generalised anxiety disorder: evaluation conducted alongside an escitalopram relapse prevention trial. Curr Med. Res. Opin. 23(10), 2543-2549 (2007).
72. Bandelow B, Stein DJ, Dolberg OT, Andersen HF, Baldwin DS. Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry 40(4), 152-156 (2007).
73. Lerner D, Adler DA, Chang H er al. Unemployment, job retention, and productivity loss among employees with depression. Pychiatr. Serv. 55(12), 1371-1378 (2004).
74. Fantino B, Moore N, Verdoux H, Auray JP. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. Int. Clin. Pychopharmacol. 22(2), 107-115 (2007).
75. Wade AG, Fernandez JL, Francois C et al. A pharmacoeconomic comparison of escitalopram and duloxetine in treatment of major depressive disorder (MDD) in the United Kingdom. Presented at: The 10th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Dublin, Ireland, 20-23 October 2007 (Abstract PMH60).
76. Lancon C, Sapin C, Note I, Farisse J. Comparison of escitalopram and citalopram in outpatients with severe major depressive disorder: a prospective, naturalistic, 8-week study. Int. J. Psych. Clin. Pract. 10(2), 131-137 (2006).
77. Moller HJ, Langer S, Schmauss M. Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany. Pharmacopsychiatry 40(2), 53-57 (2007).
78. Winkler D, Pjrek E, Moser U, Kasper S. Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria. Hum Psychopharmacol. 22(4), 245-251 (2007).
79. Wade A, Despiegel N, Heldbo Reines E. Escitalopram in the long-term treatment of major depressive disorder. Ann. Clin. Psychiatry 18(2), 83-89 (2006).
80. Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress. Anxiety 21 (1), 26-32 (2005).
81. Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 23(2), 155-167 (2005).
82. Sadri H, Mittman N. A qualitative review of recent economic evaluations of escitalopram. J. Pharm. Technol. 23, 35-40 (2007).
83. Franqois C,Henrikkson F, Toumi M, et al. A Swedish pharmacoeconomic evaluation of escitalopram, a new SSRI: comparison of cost-effectiveness between escitalopram, PR-citalopram, fluoxetine and venlafaxine. Value Health 5, 230 (2002) (Abstract).
84. Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotomn reuptake inhibitors and associated adverse drug reactions. CNS Drugs 18(13), 911-932 (2004).
85. Armstrong EP, Skrepnek GH, Haim Erder M. Cost-utility comparison of escitalopram and sertraline in die treatment of major depressive disorder. Curr. Med. Res. Opin. 23(2), 251-258 (2007).
86. Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-fine treatment of major depressive disorder in Austria. Curr. Med. Res. Opin. 20(6), 869-878 (2004).
87. Sorensen J, Stage KB, Damsbo N, Lay AL, Hemels ME. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nord. J. Psychiatry 61(2), 100-108 (2007).
88. Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int. J. Clin. Pract. 61(4), 702-710 (2007).
89. Doyle JJ, Casciano J, Arikian S et al. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health 40(1), 16-31 (2001).
90. Montgomery SA, Huusom, AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 50(l), 57-64 (2004).
91. Kulp W, von der Schulenburg JM, Greiner W. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. Eur. J. Health Econ. 60(4), 317-321 (2005).
92. Wade AG, Tourmi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-fine treatment ofmajor depressive disorder in the UK. Curr. Med. Res. Opin. 21(4), 631-642 (2005).
93. Hemels ME, Sorenson J, Stage KB, Damsbo N, Le Lay A. Probabilistic cost-effectiveness model of escitalopram compared with citalopram and venlafaxine in the first-line treatment of major depressive disorder in Denmark. Presented at: The 46th Annual Meeting of the Scandinavian College of Neuropsychopharmacology. Helsingør, Denmark, 27-30 April 2005 (Poster)
94. Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin. Ther. 27(4), 486-496 (2005).
95. Francois C, Toumi M, Aakhus AM, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur. J. Health Econ. 4(l), 12-19 (2003).
96. Danchenko N, Hansen K, Holsten F, Despiegel N. Cost-effectiveness of escitalopram versus citalopram and venlafaxine in treatment of severe depression in Norway. Presented at: The 6th World Congress on Health Economics (iHEA). Copenhagen, Denmark, 8-11 July 2007 (Abstract).
97. Erder MH, Sharma D, Jonas JM. A comparison of total direct medical costs to managed care of escitalopram versus venlafaxine XR treatment in generalized anxiety disorder. Int. J. Neuropsychopharmacol. 9 (Suppl. 1), S120 (2006).
98. Montgomery SA, Francois C, Despiegel N. Escitalopram versus placebo in social anxiety disorder (SAD): better effectiveness, lower costs and improved quality of life. Eur. Neuropsychopharmacol. 13 (Suppl. 4), S369 (2003) (Abstract P.363.038).
99. Servant D, Montgomery SA, François C. Relapse in social anxiety disorder (SAD): costs and quality of life. Presented at: The 16th European College of Neuropsychopharmacology (ECNP). Prague, Czech Republic 10-24 September 2003 (abstract P.3.040).
100. Gommoll C, Korotzer A, Chen S. Placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Presented at: The 26th Annual Meeting of the Anxiety Disorders Association of America. Miami, FL, USA, 23-26 March 2006 (Abstract).
101. Lecrubier Y. The burden of depression and anxiety in general medicine. J. Clin. Psychiatry 62(Suppl. 8), 4-9; discussion 10-11 (2001).
102. Ventura D, Armstrong EP, Skrepnek GH, Haim Erder M. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr. Med. Res. Opin. 23(2),245-250 (2007).
103. Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Presented at: The 20th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Bordeaux, France, 22-25 August 2004 (Poster).
104. Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann. Pharmacother. 38(6), 954-960 (2004).
105. Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur. Neuropsychopharmacol. 15(4), 445-452 (2005).